Liquidia reports Q2 revenue of $6.5 mln, net loss widens

Liquidia

12/08/2025 11:39

Corrects revenue figure throughout to $8.8 mln from $6.5 mln, removes reference to product revenue from Overview

Overview

Liquidia reports Q2 revenue of $8.8 mln following YUTREPIA launch

Net loss for Q2 widens to $41.6 mln due to commercialization costs

Co reports positive interim ASCENT trial data for YUTREPIA

Outlook

Liquidia plans to expand market access for YUTREPIA in Q3 and Q4

Company aims to scale YUTREPIA access and expand clinical programs

Liquidia to present detailed clinical data at conferences in September and October

Company targets occupancy of new manufacturing space in 2026

Result Drivers

YUTREPIA LAUNCH - Over 900 unique patient prescriptions and 550 patient starts within 11 weeks post-approval, reflecting strong demand

COMMERCIALIZATION COSTS - Increased expenses due to YUTREPIA launch and legal fees contributed to wider net loss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$8.84 mln
Q2 Net Income
-$41.58 mln
Q2 Basic EPS
-$0.49
Q2 Operating Income
-$37.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Liquidia Corp is $32.00, about 33.8% above its August 11 closing price of $21.20

Press Release: ID:nGNXbb1x4H

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)